A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumors.
Chuk MK, Aikin A, Whitcomb T, Widemann BC, Zannikos P, Bayever E, Balis FM, Fox E.
SourceChildren's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania. meredith.chuk@chp.edu.
Article first published online: 27 JUL 2012
Abstract
BACKGROUND: The objectives of this phase I study were to determine the maximum tolerated dose (MTD), toxicity profile, and pharmacokinetics of a 24-hour continuous intravenous infusion of trabectedin administered to children and adolescents with refractory or relapsed solid tumors.
PROCEDURE: Patients between the ages of 4 and 16 years old with refractory solid tumors received trabectedin as a 24-hour infusion every 21 days. Dexamethasone and prophylactic growth factor support were administered with each cycle. Pharmacokinetic studies were conducted during cycle 1.
RESULTS: Patients (n = 12) median (range) age 14.5 (8-16) years received trabectedin at 1.1 (n = 3), 1.5 (n = 6), or 1.7 (n = 3) mg/m(2) . At the 1.5 mg/m(2) dose level, one patient had dose limiting anorexia and fatigue. At 1.7 mg/m(2) , two patients experienced dose limiting toxicity, dehydration, and gamma-glutamyl transpeptidase elevation. Non-dose limiting toxicities included elevated serum transaminases, myelosuppression, nausea, emesis, and fatigue. Plasma pharmacokinetic parameters were similar to historical data in adults. One partial response was observed in a patient with neuroendocrine carcinoma. Stable disease (≥6 cycles) was achieved in three patients (osteosarcoma n = 2, desmoplastic small round cell tumor n = 1).
CONCLUSIONS: The MTD of trabectedin in pediatric patients with refractory solid tumors is 1.5 mg/m(2) IV over 24 hours every 21 days. Dexamethasone to ameliorate hepatic toxicity and prophylactic growth factor support are required. Pediatr Blood Cancer © 2012 Wiley Periodicals, Inc.
Copyright © 2012 Wiley Periodicals, Inc.
02 agosto 2012
Grifols , Morgan Stanley suben su Precio Objetivo de 21,39 euros a 23,6 y Aconsejan SobrePonderar .
Grifols convence a los brokers .02/08/2012 - 08:58 .
Aunque hay a quien le da vértigo los niveles a los que cotiza Grifols, lo cierto es que este valor saca pecho y supera al Ibex 35 día a día, lo que hoy le vale una mejora de consejo en un día en el que los brokers se muestran más cautos que osados a la hora de lanzar sus recomendaciones de inversión.
La astronómica revalorización del 80% desde enero de Grifols contrasta de lleno con la evolución de su índice de referencia, pues el Ibex 35 ha perdido desde inicio de año un 26%. Algunos expertos llevan meses advirtiendo de que el valor no puede seguir nadando a contracorriente. Sin embargo, hoy desde Morgan Stanley hacen un guiño a Grifols y suben su precio objetivo de 21,39 euros a 23,6, zona en la que actualmente cotiza. Aconsejan sobreponderar la acción basándose en un incremento del 8% de las estimaciones para el Ebtida, las posibles sinergias de la compañía y el éxito en la fase III de su fármaco contra el Alzheimer.